Related Experiment Videos
Selection of drug therapy in stable angina pectoris
1Second Division of Cardiology, Ospedale Niguarda Ca' Granda, Milan, Italy. ssavoni@tin.it
Insights
Drug therapy for stable angina aims to prevent cardiac events and relieve chest pain. Aspirin and lipid-lowering drugs are proven for prevention, while tailored anti-ischemic drugs manage ischemia effectively.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Stable angina management involves preventing major cardiac events and controlling ischemic symptoms.
- Primary prevention studies are limited due to sample size and follow-up requirements.
- Aspirin and lipid-lowering agents are established for event prevention in stable angina.
Purpose of the Study:
- To review current strategies for drug therapy in stable angina.
- To discuss the dual aims of preventing cardiac events and managing ischemia.
- To explore patient-specific approaches for optimizing anti-ischemic drug selection.
Main Methods:
- Review of existing literature on stable angina pharmacotherapy.
- Analysis of the roles of aspirin, lipid-lowering agents, and anti-ischemic drugs.
- Evaluation of diagnostic tools for guiding anti-ischemic therapy selection.
Main Results:
- Aspirin and lipid-lowering agents are key for preventing major cardiac events.
- Anti-ischemic drugs target the imbalance between myocardial oxygen supply and demand.
- Exercise and provocative tests can guide selection between beta-blockers and calcium antagonists.
- Optimally titrated monotherapy is as effective as combination therapy for ischemia reduction in individual patients.
Conclusions:
- Combination therapy for stable coronary artery disease should comprise an individually selected, titrated anti-ischemic agent, aspirin, and a lipid-lowering agent if hypercholesterolemia is present.
- Tailoring therapy based on ischemia-inducing factors and patient response is crucial.
- Standard exercise and provocative tests aid in selecting appropriate anti-ischemic agents.
Abstract:
Drug therapy in stable angina has two aims: the prevention of major cardiac events (such as unstable angina, myocardial infarction, or death) and the control of chest pain and transient myocardial ischemia. Given the low incidence of major cardiac events in patients with stable angina, primary preventive studies are scarce because they require a large sample size and long-term follow-up. Thus far, only aspirin and some lipid-lowering agents have been shown to be effective for this purpose. Antiischemic drugs reduce the imbalance between myocardial oxygen demand and supply, either by reducing oxygen consumption or by increasing coronary blood flow. The ideal approach would be to target drug therapy against the ischemia-inducing factor in each patient. The characteristics of anginal symptoms do not seem to help in selecting medical therapy, whereas a standard exercise test and a provocative test of coronary vasoconstriction may provide useful information in order to select patients who will preferentially respond to either a beta-blocker or a calcium antagonist. The combination of two or more anti-ischemic drugs does not seem to be any more effective than an adequately titrated monotherapy in reducing the occurrence of myocardial ischemia in individual patients. Combination therapy in stable coronary artery disease should include an individually selected and optimally titrated anti-ischemic agent and aspirin, with the addition of a lipid-lowering agent in patients with even mild hypercholesterolemia.